Step 1 of 2
The treatment landscape of R/R mantle cell lymphoma continues to evolve as the use of covalent BTK inhibitors further expands into the first-line setting. These slides contain the latest data, guidelines, and expert recommendations for managing R/R disease post covalent BTK inhibitor. Highlights include the similarities and differences between small molecules pirtobrutinib and sonrotoclax including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, and implementing treatment in community practices. They also include the efficacy, safety, and best practices of CAR T-cell therapy and bispecific antibodies.